Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC Meeting Abstract


Authors: Janne, P. A.; Yu, H. A.; Johnson, M. L.; Vigliotti, M.; Shipitofsky, N.; Guevara, F. M.; Chen, S.; Yu, C.
Abstract Title: Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC
Meeting Title: 54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 15 Suppl.
Meeting Dates: 2018 Jun 1-5
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-05-20
Start Page: 487s
Language: English
ACCESSION: WOS:000442916008014
DOI: 10.1200/JCO.2018.36.15_suppl.TPS9110
PROVIDER: wos
Notes: Meeting Abstract: TPS9110 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Helena Alexandra Yu
    285 Yu